Evidence map›Paper›PMID 36339908›Full record

ArticleAME case reports2022

The unusual first sign of presentation of renal cell carcinoma: a rare case report.

Rocco Morra, Antonio D'Ambrosio, Erica Pietroluongo, Pietro De Placido, Liliana Montella, Vitantonio Del Deo, Marianna Tortora, Elide Matano, Vincenzo Damiano, Giovannella Palmieri and 2 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in AME case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Rocco Morra *Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Antonio D'Ambrosio *Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Erica PietroluongoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Pietro De PlacidoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Liliana MontellaOncology Operative Unit, "Santa Maria delle Grazie" Hospital (ASL NA 2 NORD), Pozzuoli, Italy.
Vitantonio Del DeoAzienda Ospdaliera Universitaria Federico II of Naples, Clinical Department of Oncology and Hematology, Naples, Italy.
Marianna TortoraAzienda Ospdaliera Universitaria Federico II of Naples, Clinical Department of Oncology and Hematology, Naples, Italy.
Elide MatanoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Vincenzo DamianoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Giovannella PalmieriCoordinating Rare Tumors Reference Center of Campania Region (CRCTR), Clinical Department of Oncology and Hematology, Azienda Ospdaliera Universitaria Federico II of Naples, Naples, Italy.
Sabino De PlacidoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Mario GiulianoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
University of Naples Federico II · ITRegione Campania · ITOspedale Santa Maria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renal cell carcinoma (RCC) usually is characterized by a slow pattern of growth, although with an unpredictable evolution and metastatic potential, favored by its extensive vascularity and related high angioinvasive profile. The most common sites of metastases from kidney cancer are lung, lymph nodes, bone and liver; whereas orbital metastases are very uncommon. In more than 25% of cases, orbital metastases are the first manifestation of a primary tumor of unknown origin. The clinical features of orbital metastases from kidney cancer are non-specific and could divert attention from the real problem. Case Description: In this article, we describe the case of a 72-year-old male patient reporting a painful mass on the right orbit, with exophthalmos and ptosis, as the first and unique signs of a previously undetected advanced RCC. Due to the clinical conditions, the patient underwent palliative radiation therapy delivered to the orbital lesion with the scope to relieve pain; subsequently started systemic therapy with pazopanib at the dose of 800 mg daily. Unfortunately, he did not achieve any benefit from systemic therapy, his conditions progressively worsened, and he finally passed away after four months of treatment due to rapid disease progression. Conclusions: Despite its rarity, differential diagnosis of an orbital lesion should always consider the possibility of metastasis from RCC, performing an appropriate radiological evaluation.

Indexed as

Case reportorbital metastasisrenal carcinomaundiagnosed cancer

Identifiers

PMID36339908
PMCPMC9634463
OpenAlexW4290702621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.